HeartFlow, Inc. (HTFL) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Rick Wise.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rick Wise’s rating is based on HeartFlow, Inc.’s innovative technology and promising growth prospects. The company’s FFR CT and Plaque Analysis technology is seen as a game-changer in coronary artery disease management, providing significant value to patients, physicians, and hospitals. This technology enhances decision-making, leading to improved procedure efficiency and economic benefits.
Additionally, HeartFlow’s strong financial performance, with a 38% revenue growth and 75% gross margins in the first half of 2025, supports the Buy rating. The anticipated reimbursement milestone for their plaque analysis technology is expected to further drive growth. With increasing adoption of their technology and expanding commercial presence, HeartFlow is well-positioned for sustained growth and improved margins in the coming years.
In another report released today, Piper Sandler also initiated coverage with a Buy rating on the stock with a $38.00 price target.